Literature DB >> 35778628

ASO Author Reflections: Sarcoma Organoids: Neutralizing the Word "Rare" in Rare Cancers.

Steven D Forsythe1,2,3, Hemamylammal Sivakumar1,4, Richard A Erali1,3,5,6, Aleksander Skardal1,2,4,7, Konstantinos I Votanopoulos8,9,10,11,12.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35778628     DOI： 10.1245/s10434-022-12089-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   4.339


× No keyword cloud information.
  4 in total

1.  Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.

Authors:  Konstantinos I Votanopoulos; Steven Forsythe; Hemamylammal Sivakumar; Andrea Mazzocchi; Julio Aleman; Lance Miller; Edward Levine; Pierre Triozzi; Aleksander Skardal
Journal:  Ann Surg Oncol       Date:  2019-12-19       Impact factor: 5.344

2.  Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.

Authors:  Konstantinos I Votanopoulos; Andrea Mazzocchi; Hemamylammal Sivakumar; Steven Forsythe; Julio Aleman; Edward A Levine; Aleksander Skardal
Journal:  Ann Surg Oncol       Date:  2018-11-09       Impact factor: 5.344

Review 3.  Organoids in cancer research.

Authors:  Jarno Drost; Hans Clevers
Journal:  Nat Rev Cancer       Date:  2018-07       Impact factor: 60.716

4.  Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study.

Authors:  Steven D Forsythe; Richard A Erali; Shyama Sasikumar; Preston Laney; Ethan Shelkey; Ralph D'Agostino; Lance D Miller; Perry Shen; Edward A Levine; Shay Soker; Konstantinos I Votanopoulos
Journal:  Clin Cancer Res       Date:  2021-07-01       Impact factor: 13.801
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.